-
1Academic Journal
Συγγραφείς: T. M. Geliashvili, A. V. Vazhenin, T. P. Berezovskaya, E. B. Vasilieva, N. G. Afanasieva, V. V. Krylov, P. I. Garbuzov, Т. М. Гелиашвили, А. В. Важенин, Т. П. Березовская, Е. Б. Васильева, Н. Г. Афанасьева, В. В. Крылов, П. И. Гарбузов
Πηγή: Head and Neck Tumors (HNT); Том 10, № 4 (2020); 16-24 ; Опухоли головы и шеи; Том 10, № 4 (2020); 16-24 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2020-0-4
Θεματικοί όροι: предабляционный уровень тиреоглобулина, positron emission tomography, differentiated thyroid cancer, radioiodine therapy, pre-ablation thyroglobulin leve, позитронная эмиссионная томография, дифференцированный рак щитовидной железы, радиойодтерапия
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/577/448; Kitahara C.M., Devesa S.S., Sosa J.A. Increases in thyroid cancer incidence and mortality-reply. JAMA 2017;318(4):390–1. DOI:10.1001/jama.2017.7910.; Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. DOI:10.1089/thy.2015.0020.; Santhanam P., Solnes L.B., Rowe S.P. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond. Med Oncol 2017;34(12):189. DOI:10.1007/s12032-017-1051-x.; Fatourechi V., Hay I.D., Mullan B.P. et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000;10(7):573–7. DOI:10.1089/thy.2000.10.573.; Sheikh A., Polack B., Rodriguez Y., Kuker R. Nuclear molecular and theranostic imaging for differentiated thyroid cancer. Mol Imaging Radionucl Ther 2017;26(Suppl 1):50–65. DOI:10.4274/2017.26.suppl.06.; Choudhury P.S., Guptа M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol 2018;91(1091):20180136. DOI:10.1259/bjr.20180136.; Rosenbaum-Krumme S.J., Gorges R., Bockisch A., Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imag 2012;39(9):1373–80. DOI:10.1007/s00259-012-2065-4.; Lee J.W., Lee S.M., Lee D.H., Kim Y.J. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med 2013;54(8):1230–6. DOI:10.2967/jnumed.112.117119.; Gaertner F.C., Okamoto S., Shiga T. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med 2015;40(5):378–83. DOI:10.1097/RLU.0000000000000699.; Nascimento C., Borget I., Al Ghuzlan A. et al. Postoperative fluorine-18-fluoro- deoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 2015;25:437–44. DOI:10.1089/thy.2014.0320.; Triviño Ibáñez E.M., Muros M.A., Torres Vela E., Llamas Elvira J.M. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma. Endocrine 2015;51(3):490–8. DOI:10.1007/s12020-015-0708-5.; Qiu Z.-L., Wei W.-J., Shen C.-T. et al. Diagnostic performance of 18F-FDG PET/ CT in papillary thyroid carcinoma with negative 131I-WBS at first postablation, negative Tg and progressively increased TgAb level. Sci Rep 2017;7(1):2849. DOI:10.1038/s41598-017-03001-7.; Ruhlmann M., Binse I., Bockisch A., Rosenbaum-Krumme S.J. Initial [18F] FDG PET/CT in high-risk DTC patients. A three-year follow-up. Nuklearmedizin 2016;55:99–103. DOI:10.3413/Nukmed-0766-15-09.; Chang Y.W., Kim H.S., Jung S.P. et al. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio. Int J Clin Oncol 2016;21:862–8. DOI:10.1007/s10147-016-0956-2.; Cho S.G., Kwon S.Y., Kim J. et al. Risk factors of malignant fluorodeoxyglucoseavid lymph node on preablation positron emission tomography in patients with papillary thyroid cancer undergoing radioiodine ablation therapy. Medicine (Baltimore) 2019;98(16):e14858. DOI:10.1097/MD.0000000000014858.; Shangguan L., Fang S., Zhang P. et al. Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy. Ann Nucl Med 2019;33:177–83. DOI:10.1007/s12149-018-01321-w.; Liu M., Cheng L., Jin Y. et al. Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep 2018;8(1):4352. DOI:10.1038/s41598-018-22656-4; Kwon S.Y., Kim J., Jung S.H. et al. Preablative stimulated thyroglobulin levels can predict malignant potential and therapeutic responsiveness of subcentimeter-sized, 18F-fluorodeoxyglucose-avid cervical lymph nodes in patients with papillary thyroid cancer. Clin Nucl Med 2016;41(1):e32–8. DOI:10.1097/RLU.0000000000000889.; https://ogsh.abvpress.ru/jour/article/view/577
-
2Academic Journal
Συγγραφείς: Geliashvili T.M., Vazhenin A.V., Berezovskaya T.P., Vasilieva E.B., Afanasieva N.G., Krylov V.V., Garbuzov P.I.
Πηγή: Head and Neck Tumors; Vol 10, No 4 (2020); 16-24 ; Опухоли головы и шеи; Vol 10, No 4 (2020); 16-24 ; 2411-4634 ; 2222-1468
Θεματικοί όροι: 18F-fluorodeoxyglucose, positron emission tomography, differentiated thyroid cancer, radioiodine therapy, pre-ablation thyroglobulin leve, 18F-фтордезоксиглюкоза, позитронная эмиссионная томография, дифференцированный рак щитовидной железы, радиойодтерапия, предабляционный уровень тиреоглобулина
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/577/448; https://ogsh.abvpress.ru/jour/article/view/577